Biopolym. Cell. 2011; 27(3):181-192.
http://dx.doi.org/10.7124/bc.0000B8
Огляди
Інгібітори лізосомних цистеїнових протеїназ
1Чорна В. І., 2Лянна О. Л.
  1. Дніпропетровський державний аграрний університет
    вул. Ворошилова, 25, Дніпропетровськ, Україна, 49600
  2. Дніпропетровська державна медична академія
    вул. Дзержинського, 9, Дніпропетровськ, Україна, 49044

Abstract

Огляд присвячено інгібіторам цистеїнових протеїназ, відомих своїм важливим значенням для багатьох біохімічних процесів, які відбуваються в живому організмі. Вони також беруть участь у виникненні та розвитку значної кількості захворювань, спричинених, серед іншого, анормальним білковим кругообігом. Одним із головних регуляторів активності зазначених протеїназ є їхні специфічні інгібітори – цистатіни. Мета даного огляду полягає у висвітленні сучасних уявлень щодо ендогенних інгібіторів лізосомних цистеїнових протеїназ та їхніх синтетичних аналогів.
Keywords: цистатини, стефіни, кініногени, цистеїнові катепсини, синтетичні інгібітори
Повний текст: (PDF, українською)

References

[1] Turk V., Turk B. Lysosomal cysteine proteases and their protein inhibitors: recent developments Acta Chim 2008 55, N 4 P. 727–738.
[2] Dickinson D. P. Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissue in health and disease Crit. Rev. Oral. Biol. Med 2002 13, N 3 P. 238–275.
[3] Lopez-Otin C., Overall C. M. Protease degradomics: a new challenge for proteomics Nat. Rev. Mol. Cell. Biol 2002 3, N 7 P. 509–519.
[4] Mason R. W. Lysosomal metabolism of proteins Subcell. Biochem 1996 27 P. 159–190.
[5] Barrett A. J. Classification of peptidases Meth. Enzymol 1994 244 P. 1–15.
[6] Turk B., Turk D., Turk V. Lysosomal cysteine proteases: more than scavengers Biochim. Biophys. Acta 2000 1477, N 1– 2 P. 98–111.
[7] Lazure C., Seidah N. G., Pelaprat D., Chretien M. Proteases and posttranslational processing of prohormones: a review Can. J. Biochem. Cell Biol 1983 61, N 7 P. 501–515.
[8] Chapman H. A. Jr., Munger J. S., Shi G. P. The role of thiol proteases in tissue injury and remodeling Am. J. Respir. Crit. Care Med 1994 150, N 6 P. S155–159.
[9] Riese R. J., Chapman H. A. Cathepsins and compartmentalization in antigen presentation Curr. Opin. Immunol 2000 12, N 1 P. 107–113.
[10] Hamilton R. T., Bruns K. A., Delgado M. A., Shim J. K., Fang Y., Denhardt D. T., Nilsen-Hamilton M. Developmental expression of cathepsin L and c-rasHa in the mouse placenta Mol. Reprod. Dev 1991 30, N 4 P. 285–292.
[11] Guicciardi M. E., Leist M., Gores G. J. Lysosomes in cell death Oncogene 2004 23, N 16 P. 2881–2890.
[12] Jedeszko C., Sloane B. F. Cysteine cathepsins in human cancer Biol. Chem 2004 385, N 11 P. 1017–1027.
[13] Hansen T., Petrow P. K., Gaumann A., Keyszer G. M., Eysel P., Eckardt A., Brauer R., Kriegsmann J. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium J. Rheumatol 2000 27, N 4 P. 859–865.
[14] Lang A., Horler D., Baici A. The relative importance of cysteine peptidases in osteoarthritis J. Rheumatol 2000 27, N 8 P. 1970–1979.
[15] Bernstein H. G., Kirschke H., Wiederanders B., Pollak K. H., Zipress A., Rinne A. The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: a review Mol. Chem. Neuropathol 1996 27, N 3 P. 225–247.
[16] Nagai A., Murakawa Y., Terashima M., Shimode K., Umegae N., Takeuchi H., Kobayashi S. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases Neurology 2000 55, N 12 P. 1828–1832.
[17] Berdowska I. Cysteine proteases as disease markers Clin. Chim. Acta 2004 342, N 1–2 P. 41–69.
[18] Dickinson D. P. Salivary (SD-type) cystatins: over one billion years in the making – but to what purpose? Crit. Rev. Oral. Biol. Med 2002 13, N 6 P. 485–508.
[19] Turk B., Bieth J. G., Bjork I., Dolenc I., Turk D., Cimerman N., Kos J., Colic A., Stoka V., Turk V. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/ or endogenous protein inhibitors, cystatins Biol. Chem. Hoppe-Seyler 1995 376, N 4 P. 225–230.
[20] Otto H. H., Schirmeister T. Cysteine proteases and their inhibitors Chem. Rev 1997 97, N 1 P. 133–172.
[21] Grzonka Z., Jankowska E., Kasprzykowski F., Kasprzykowska R., Lankiewicz L., Wiczk W., Wieczerzak., Ciarkowski J., Drabik P., Janowski R., Kozak M., Jaskolski M., Grubb A. Structural studies of cysteine proteases and their inhibitors Acta Biochim. Pol 2001 48, N 1 P. 1–20.
[22] Turk V., Bode W. The cystatins: protein inhibitors of cysteine proteinases FEBS Lett 1991 285, N 2 P. 213–219.
[23] Green G. D., Kembhavi A. A., Davies M. E., Barrett A. J. Cystatinlike cysteine proteinase inhibitors from human liver Biochem. J 1998 218, N 3 P. 939–946.
[24] Takeda A., Kobayashi S., Samejima T. Isolation and characterization of two thiol proteinase inhibitors of low molecular weight from newborn rat epidermis J. Biochem 1983 94, N 3 P. 811– 820.
[25] Turk B., Kriaj I., Turk V. Isolation and characterization of bovine stefin B Biol. Chem. Hoppe Seyler 1992 373, N 7 P. 441– 446.
[26] Lenarcic B., Ritonja A., Dolenc L., Stoka V., Berbic S., Pungercar J., Strukelj B., Turk V. Pig leukocyte cysteine proteinase inhibitor (PLCPI), a new member of the stefin family FEBS Lett 1993 336, N 2 P. 289–292.
[27] Kondo H., Ijiri S., Abe K., Maeda H., Arai S. Inhibitory effect of oryzacystatins and a truncation mutant on the replication of poliovirus in infected Vero cells FEBS Lett 1992 299, N 1 P. 48–50.
[28] Lenarcic B., Kriaj I., Zunec P., Turk V. Differences in specificity for the interactions of stefins A, B and D with cysteine proteinases FEES Lett 1996 395, N 2–3 P. 113–118.
[29] Abrahamson M. Cystatins: protein inhibitors of papain-like cysteine proteinases Ciencia e Cultura 1993 45, N 5 P. 299–304.
[30] Turk B., Krizaj I., Kralj B., Dolenc I., Popovic T., Bieth J. G., Turk V. Bovine stefin C, a new member of the stefin family J. Biol. Chem 1993 268, N 10 P. 7323–7329.
[31] Esnard F., Esnard A., Faucher D., Capony J.P., Derancourt J., Brillard M., Gauthier F. Rat cystatin C: the complete amino acid sequence reveals a site for N-glycosylation Biol. Chem. Hoppe Seyler 1990 371, suppl P. 161–166.
[32] Freije J. P., Pendas A. M., Velasco G., Roca A., Abrahamson M., Lopez-Otin C. Localization of the human cystatin D gene (CST5) to chromosome 20pll.21 by in situ hybridization Cytogen. Cell. Genet 1993 62, N 1 P. 29–31.
[33] Fossum K., Whitaker J. R. Ficin and papain inhibitor from chicken egg white Arch. Biochem. Biophys 1968 125, N 1 P. 367–375.
[34] Grubb A., Lofberg H. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenophysis Proc. Natl Acad. Sci. USA 1982 79, N 9 P. 3024–3027.
[35] Abrahamson M. Cystatins Meth. Enzymol 1994 244 P. 685–700.
[36] Abrahamson M., Ritonja A., Brown M. A., Grubb A., Machleidt W., Barrett A. J. Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin J. Biol. Chem 1987 262, N 20 P. 9688–9694.
[37] Grubb A. O., Weiber H., Lofberg H. The gamma-trace concentration of normal human seminal plasma is thirty-six times that of normal human blood plasma Scand. J. Clin. Lab. Invest 1983 43, N 5 P. 421–425.
[38] Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids Clin. Nephrol 1992 38, Suppl 1 P. S20–S27.
[39] Isemura S., Saitoh E., Sanada K., Minakata K. Identification of full-sized forms of salivary (S-type) cystatins (cystatin SN, cystatin SA, cystatin S, and two phosphorylated forms of cystatin S) in human whole saliva and determination of phosphorylation sites of cystatin S J. Biochem 1991 110, N 4 P. 648–654.
[40] Balbin M., Freije J. P., Abrahamson M., Velasco G., Grubb A., Lopez-Otin C. A sequence variation in the human cystatin D gene resulting in an amino acid (Cys/Arg) polymorphism at the protein level Hum. Genet 1993 90, N 6 P. 668–669.
[41] Freije J. P., Balbin M., Abrahamson M., Velasco G., Dalboge H., Grubb A., Lopez-Otin C. Human cystatin D. cDNA cloning, characterization of the Escherichia coli expressed inhibitor, and identification of the native protein in saliva J. Biol. Chem 1993 268, N 21 P. 15737–15744.
[42] Ni J., Abrahamson M., Zhang M., Fernandez M. A., Grubb A., Su J., Yu G. L., Li Y., Parmelee D., Xing L., Coleman T. A., Gentz S., Thotakura R., Nguyen N., Hesselberg M., Gentz R. Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins J. Biol. Chem 1997 272, N 16 P. 10853–10858.
[43] Sotiropoulou G., Anisowicz A., Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer J. Biol. Chem 1997 272, N 2 P. 903–910.
[44] Ni J., Fernandez M. A., Danielsson L., Chillakuru R. A., Zhang J., Grubb A., Su J., Gentz R., Abrahamson M. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor J. Biol. Chem 1998 273, N 38 P. 24797–24804.
[45] Lalmanach G., Naudin C., Lecaille F., Fritz H. Kininogens: more than cysteine protease inhibitors and kinin precursors Biochimie 2010 92, N 11 P. 1568–1579.
[46] Zhang J. C., Claffey K., Sakthivel R., Darzynkiewicz Z., Shaw D. E., Leal J., Wang Y. C., Lu F. M., McCrae K. R. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5 FASEB J 2000 14, N 15 P. 2589–2600.
[47] DeLa Cadena R. A., Colman R. W. Structure and functions of human kininogens Trends Pharmacol. Sci 1991 12, N 7 P. 272–275.
[48] Brown W.M., Dziegielewska K.M. Friends and relations of the cystatin superfamily – new members and their evolution Protein Sci 1997 6, N 1 P. 5–12.
[49] Murzin A. Sweet-tasting protein monellin is related to the cystatin family of thiol proteinase inhibitors J. Mol. Biol 1993 230, N 2 P. 689–694.
[50] Grubb A., Abrahamson M., Olafsson I., Trojnar J., Kasprzykowska R., Kasprzykowski F., Grzonka Z. Synthesis of cysteine proteinase inhibitors structurally based on the proteinase interacting N-terminal region of human cystatin C Biol. Chem. HoppeSeyler 1990 371, suppl P. 137–144.
[51] Hall A., Dalboge H., Grubb A., Abrahamson M. Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-11) for cysteine endopeptidase inhibition Biochem. J 1993 291, Pt 1 P. 123–129.
[52] Hall A., Ekiel I., Mason R. W., Kasprzykowski F., Grubb A., Abrahamson M. Structural basis for different inhibitory specificities of human cystatins C and D Biochemistry 1998 37, N 12 P.4 071–4079.
[53] Hall A., Hakansson K., Mason R. W., Grubb A., Abrahamson M. Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivityconferring residue in the inhibition of mammalian cysteine peptidases J. Biol. Chem 1995 270, N 10 P. 5115–5121.
[54] Buchanan J. M. The amidotransferases Adv. Enzymol. Relat. Areas. Mol. Biol 1973 39 P. 91–183.
[55] Crawford C., Mason R. W., Wikstrom P., Shaw E. The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B Biochem J 1988 253, N 3 P. 751–758.
[56] Wilcox D., Mason R. W. Labelling of cysteine proteinases in purified lysosomes Biochem. Soc. Trans 1989 17, N 6 P. 1080–1081.
[57] Wilk S., Friedman T. C., Kline T. B. Pyroglutamyl diazomethyl ketone: potent inhibitor of mammalian pyroglutamyl peptide hydrolase Biochem. Biophys. Res. Commun 1985 130, N 2 P. 662–668.
[58] Bjorck L., Akesson P., Bohus M., Trojnar J., Abrahamson M., Olafsson I., Grubb A. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor Nature 1989 337, N 6205 P. 385–386.
[59] Ambroso J. L., Harris C. In vitro embryotoxicity of the cysteine proteinase inhibitors benzyloxycarbonyl-phenylalanine-alanine-diazomethane (Z-Phe-Ala-CHN2) and benzyloxycarbonylphenylalanine-phenylalanine-diazomethane (Z-Phe-Phe-CHN2) Teratology 1994 50, N 3 P. 214–228.
[60] Hanada K., Tamai M., Yamagishi M., Ohmura S., Sawada J., Tanaka I. Isolation and characterization of E 64, a new thiol protease inhibitor Agr. Biol. Chem 1978 42, N 3 P. 523–528.
[61] Barrett A. J., Kembhavi A. A., Brown M. A., Kirschke H., Knight C. G., Tamai M., Hanada K. L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L Biochem. J 1982 201, N 1 P. 189–198.
[62] Schaschke N., Assfalg-Machleidt I., Machleidt W., Turk D., Moroder L. E-64 analogoues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group Bioorg. Med. Chem 1997 5, N 9 P. 1789–1797.
[63] Matsumoto K., Yamamoto D., Ohishi H., Tomoo K., Ishida T., Inoue M., Sadatome T., Kitamura K., Mizuno H. Mode of binding of E-64-c, a potent thiol protease inhibitor, to papain as determined by X-ray crystal analysis of the complex FEBS Lett 1989 245, N 1–2 P. 177–180.
[64] Turk D., Podobnik M., Popovic T., Katunuma N., Bode W., Huber R., Turk V. Crystal structure of cathepsin B inhibited with CA030 at 2.0-C resolution: a basis for the design of specific epoxysuccinyl inhibitors Biochemistry 1995 34, N 14 P. 4791–4797.
[65] Murata M., Miyashita S., Yokoo C., Tamai M., Hanada K., Hatayama K., Towatari T., Nikawa T., Katunuma N. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro FEBS Lett 1991 280, N 2 P. 307–310.
[66] Sumiya S., Yoneda T., Kitamura K., Murata M., Yokoo C., Tamai M., Yamamoto A., Inoue M., Ishida T. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction Chem. Pharm. Bull. (Tokyo) 1992 40, N 2 P. 299–303.
[67] Gour-Salin B. J., Lachance P., Plouffe C., Storer A. C., Menard R. Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B J. Med. Chem 1993 36, N 6 P. 720–725.
[68] Tamai M., Matsumoto K., Omura S., Koyama I., Ozawa Y., Hanada K. In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64 J. Pharmacobiodyn 1986 9, N 8 P. 672–677.
[69] Huang Z., McGowan E. B., Detwiler T. C. Ester and amide derivatives of E64c as inhibitors of platelet calpains J. Med. Chem 1992 35, N 11 P. 2048–2054.
[70] McGowan E. B., Becker E., Detwiler T. C. Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d Biochem. Biophys. Res. Commun 1989 158, N 2 P. 432–435.
[71] Noda T., Isogai K., Katunuma N., Tarumoto Y., Ohzeki M. Effects of cathepsin B, H, and D in pectoral muscle of dystrophic chickens (line 413) of in vivo administration of E-64-c (N[N-(L-3-transcarboxyoxirane-2-carbonyl)-L-leucyl]-3-methyl-butylamine) J. Biochem 1981 90, N 3 P. 893–896.
[72] Bromme D., Kaleta J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design Curr. Pharm. Des 2002 8, N 18 P. 1639–1658.
[73] Handbook of proteolytic enzymes / Eds A. J. Barrett, N. D. Rawlings, J. F. Woessner New York: Acad. press, 1998 1666 p.
[74] Buttle D. J., Ritonja A., Dando P. M., Abrahamson M., Shaw E. N., Wikstrom P., Turk V., Barrett A. J. Interactions of papaya proteinase IV with inhibitors FEBS Lett 1990 262, N 1 P. 58–60.
[75] Bode W., Engh R., Musil D., Thiele U., Huber R., Karshikov A., Brzin J., Kos J., Turk V. The 2.0 C X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases EMBO J 1988 7, N 8 P. 2593–2599.
[76] Kos J., Schweiger A. Cathepsins and cystatins in extracellular fluids – useful biological markers in cancer Radiol. Oncol 2002 36, N 2 P. 176–179.
[77] Chorna V. I., Kakadiy O. L. Lysosomal cystein proteinases in malignant growth Oncology 2004 6, N 2 P. 84–89.
[78] Kos J., Werle B., Lah T., Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer Int. J. Biol. Markers 2000 15, N 1 P. 84–89.
[79] Lyanna O. L., Chorna V. I. Endogenous inhibitor of cysteine cathepsin L from human brain Med. Chem 2004 6, N 3 P. 107–109.
[80] Kos J., Krasovec M., Cimerman N., Nielsen H. J., Christensen I. J., Brunner N. Cysteine proteinase inhibitors stefin A, stefin B and cystatin C in sera from patients with colorectal cancer: relation to prognosis Clin. Cancer. Res 2000 6, N 2 P. 505–511.
[81] Luthgens K., Ebert W., Trefz G., Gabrijelcic D., Turk V., Lah T. Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients Cancer Detect. Prev 1993 17, N 3 P. 387–397.
[82] Lerner U. H., Johansson L., Ranjso M., Rosenquist J. B., Reinholt F. P., Grubb A. Cystatin C, and inhibitor of bone resorption produced by osteoblasts Acta Physiol. Scand 1997 161, N 1 P. 81–92.